Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Current Leases (2020 - 2025)

Historic Current Leases for Mereo BioPharma (MREO) over the last 6 years, with Q3 2025 value amounting to $397000.0.

  • Mereo BioPharma's Current Leases fell 4605.98% to $397000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $397000.0, marking a year-over-year decrease of 4605.98%. This contributed to the annual value of $707000.0 for FY2024, which is 843.56% up from last year.
  • Mereo BioPharma's Current Leases amounted to $397000.0 in Q3 2025, which was down 4605.98% from $601000.0 recorded in Q2 2025.
  • Mereo BioPharma's Current Leases' 5-year high stood at $2.7 million during Q2 2021, with a 5-year trough of $397000.0 in Q3 2025.
  • Its 5-year average for Current Leases is $1.1 million, with a median of $693000.0 in 2024.
  • Within the past 5 years, the most significant YoY rise in Mereo BioPharma's Current Leases was 5462.94% (2021), while the steepest drop was 8034.35% (2021).
  • Quarter analysis of 5 years shows Mereo BioPharma's Current Leases stood at $2.4 million in 2021, then plummeted by 76.15% to $564000.0 in 2022, then rose by 15.6% to $652000.0 in 2023, then grew by 8.44% to $707000.0 in 2024, then crashed by 43.85% to $397000.0 in 2025.
  • Its Current Leases stands at $397000.0 for Q3 2025, versus $601000.0 for Q2 2025 and $747000.0 for Q1 2025.